| YAP/TAZ and ATF4 drive resistance to Sorafenib in hepatocellular carcinoma by preventing ferroptosis R Gao, RKR Kalathur, M Coto‐Llerena, C Ercan, D Buechel, S Shuang, ... EMBO molecular medicine 13 (12), e14351, 2021 | 243 | 2021 |
| Donor and recipient IL28B polymorphisms in HCV-infected patients undergoing antiviral therapy before and after liver transplantation M Coto-Llerena, S Perez-Del-Pulgar, G Crespo, JA Carrión, SM Martínez, ... American Journal of Transplantation 11 (5), 1051-1057, 2011 | 96 | 2011 |
| Genetic profiling using plasma-derived cell-free DNA in therapy-naïve hepatocellular carcinoma patients: a pilot study CKY Ng, GG Di Costanzo, N Tosti, V Paradiso, M Coto-Llerena, ... Annals of Oncology 29 (5), 1286-1291, 2018 | 90 | 2018 |
| SOCS1 is an inducible negative regulator of interferon λ (IFN-λ)–induced gene expression in vivo T Blumer, M Coto-Llerena, FHT Duong, MH Heim Journal of Biological Chemistry 292 (43), 17928-17938, 2017 | 66 | 2017 |
| High expression of FAP in colorectal cancer is associated with angiogenesis and immunoregulation processes M Coto-Llerena, C Ercan, V Kancherla, S Taha-Mehlitz, ... Frontiers in oncology 10, 979, 2020 | 58 | 2020 |
| Integrative proteogenomic characterization of hepatocellular carcinoma across etiologies and stages CKY Ng, E Dazert, T Boldanova, M Coto-Llerena, S Nuciforo, C Ercan, ... Nature communications 13 (1), 2436, 2022 | 54 | 2022 |
| Microbiota-induced tissue signals regulate ILC3-mediated antigen presentation FM Lehmann, N von Burg, R Ivanek, C Teufel, E Horvath, A Peter, ... Nature communications 11 (1), 1794, 2020 | 50 | 2020 |
| Hepatitis C virus superinfection of liver grafts: a detailed analysis of early exclusion of non-dominant virus strains S Ramirez, S Perez-del-Pulgar, JA Carrion, M Coto-Llerena, L Mensa, ... Journal of General Virology 91 (5), 1183-1188, 2010 | 40 | 2010 |
| USP29-mediated HIF1α stabilization is associated with Sorafenib resistance of hepatocellular carcinoma cells by upregulating glycolysis R Gao, D Buechel, RKR Kalathur, MF Morini, M Coto-Llerena, C Ercan, ... Oncogenesis 10 (7), 52, 2021 | 35 | 2021 |
| Hepatocellular carcinoma xenografts established from needle biopsies preserve the characteristics of the originating tumors T Blumer, I Fofana, MS Matter, X Wang, H Montazeri, D Calabrese, ... Hepatology communications 3 (7), 971-986, 2019 | 28 | 2019 |
| Combinations of simple baseline variables accurately predict sustained virological response in patients with recurrent hepatitis C after liver transplantation G Crespo, JA Carrión, M Coto-Llerena, Z Mariño, S Lens, ... Journal of gastroenterology 48, 762-769, 2013 | 25 | 2013 |
| Selective inhibition of hepatitis C virus infection by hydroxyzine and benztropine L Mingorance, M Friesland, M Coto-Llerena, S Pérez-del-Pulgar, L Boix, ... Antimicrobial agents and chemotherapy 58 (6), 3451-3460, 2014 | 24 | 2014 |
| Adenylosuccinate lyase is oncogenic in colorectal cancer by causing mitochondrial dysfunction and independent activation of NRF2 and mTOR-MYC-axis S Taha-Mehlitz, G Bianco, M Coto-Llerena, V Kancherla, GR Bantug, ... Theranostics 11 (9), 4011, 2021 | 23 | 2021 |
| Interplay between basic residues of hepatitis C virus glycoprotein E2 with viral receptors, neutralizing antibodies and lipoproteins G Koutsoudakis, J Dragun, S Perez-del-Pulgar, M Coto-Llerena, L Mensa, ... PloS one 7 (12), e52651, 2012 | 21 | 2012 |
| Determination of IL28B polymorphisms in liver biopsies obtained after liver transplantation M Coto-Llerena, G Crespo, P González, G Koutsoudakis, R Miquel, ... Journal of Hepatology 56 (2), 355-358, 2012 | 21 | 2012 |
| Infiltration by IL22-producing T cells promotes neutrophil recruitment and predicts favorable clinical outcome in human colorectal cancer N Tosti, E Cremonesi, V Governa, C Basso, V Kancherla, M Coto-Llerena, ... Cancer immunology research 8 (11), 1452-1462, 2020 | 19 | 2020 |
| Cell culture replication of a genotype 1b hepatitis C virus isolate cloned from a patient who underwent liver transplantation G Koutsoudakis, S Perez-del-Pulgar, M Coto-Llerena, P Gonzalez, ... PloS one 6 (8), e23587, 2011 | 17 | 2011 |
| Discovery of synthetic lethal interactions from large-scale pan-cancer perturbation screens S Srivatsa, H Montazeri, G Bianco, M Coto-Llerena, M Marinucci, CKY Ng, ... Nature communications 13 (1), 7748, 2022 | 15 | 2022 |
| Interferon lambda 4 impairs hepatitis C viral antigen presentation and attenuates T cell responses Q Chen, M Coto-Llerena, A Suslov, RD Teixeira, I Fofana, S Nuciforo, ... Nature Communications 12 (1), 4882, 2021 | 15 | 2021 |
| Transcriptional Enhancer Factor Domain Family member 4 Exerts an Oncogenic Role in Hepatocellular Carcinoma by Hippo‐Independent Regulation of Heat Shock Protein 70 Family Members M Coto‐Llerena, N Tosti, S Taha‐Mehlitz, V Kancherla, V Paradiso, ... Hepatology communications 5 (4), 661-674, 2021 | 15 | 2021 |
